Section Arrow
Quote
ELTX.NASDAQ
- Elicio Therapeutics
Quotes are at least 15-min delayed:2025/01/13 09:07 EST
Last
 --
-- (--)
Day High 
-- 
Prev. Close
6.13 
1-M High
6.4 
Volume 
-- 
Bid
6.13
Ask
9.8
Day Low
-- 
Open
-- 
1-M Low
4.7 
Market Cap 
66.15M 
Currency USD 
P/E 5.96 
%Yield -- 
10-SMA 5.47 
20-SMA 5.27 
50-SMA 5.09 
52-W High 11.45 
52-W Low 2.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.44/-3.59
Enterprise Value
72.16M
Balance Sheet
Book Value Per Share
-1.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.30M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2025/01/13 09:07 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.